Quantitative global proteome and phosphorylome analyses reveal potential biomarkers in kidney cancer

Xu,Liwei; Lu,Zeyi; Yu,Shicheng; Li,Gonghui; Chen,Yuanlei

doi:10.3892/or.2021.8188

Quantitative global proteome and phosphorylome analyses reveal potential biomarkers in kidney cancer

Authors:
- Liwei Xu
- Zeyi Lu
- Shicheng Yu
- Gonghui Li
- Yuanlei Chen
View Affiliations

Affiliations: Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310016, P.R. China
Published online on: September 15, 2021 https://doi.org/10.3892/or.2021.8188
Article Number: 237
Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Currently, high‑throughput quantitative proteomic and transcriptomic approaches have been widely used for exploring the molecular mechanisms and acquiring biomarkers for cancers. Our study aimed to illuminate the multi-dimensional molecular mechanisms underlying renal cell carcinoma (RCC) via investigating the quantitative global proteome and the profile of phosphorylation. A total of 5,428 proteins and 8,632 phosphorylation sites were quantified in RCC tissues, with 709 proteins and 649 phosphorylation sites found to be altered in expression compared with the matched adjacent non‑tumor tissues. These differentially expressed proteins were mainly involved in metabolic process terms involving the glycolysis pathway, oxidative phosphorylation and fatty acid metabolism which have been considered to be a potential mechanism of RCC progression. Moreover, phosphorylation analysis indicated that these upregulated phosphorylated proteins are implicated in the glucagon signaling pathway and cholesterol metabolism, while the downregulated phosphorylated proteins were found to be predominantly involved in glycolysis, the pentose phosphate pathway, carbon metabolism and biosynthesis of amino acids. In addition, several new candidate proteins, CD14, MPO, NCF2, SOD2, PARP1, were found to be upregulated and MUT, ACADM, PCK1 were downregulated in RCC. These proteins may be recognized as new biomarkers for RCC. These findings could broaden our insight into the underlying molecular mechanisms of RCC and identify candidate biomarkers for the treatment of RCC.

View Figures

View References

1	Smith RA, Andrews K, Brooks D, DeSantis CE, Fedewa SA, Lortet-Tieulent J, Manassaram-Baptiste D, Brawley OW and Wender RC: Cancer screening in the United States, 2016: A review of current American cancer society guidelines and current issues in cancer screening. CA Cancer J Clin. 66:96–114. 2016. View Article : Google Scholar : PubMed/NCBI
2	Owens B: Kidney cancer. Nature. 537:S972016. View Article : Google Scholar : PubMed/NCBI
3	Chow WH, Dong LM and Devesa SS: Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 7:245–257. 2010. View Article : Google Scholar : PubMed/NCBI
4	Jonasch E, Gao J and Rathmell WK: Renal cell carcinoma. BMJ. 349:g47972014. View Article : Google Scholar : PubMed/NCBI
5	Zarrabi K, Fang C and Wu S: New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy. J Hematol Oncol. 10:382017. View Article : Google Scholar : PubMed/NCBI
6	Sánchez-Gastaldo A, Kempf E, González Del Alba A and Duran I: Systemic treatment of renal cell cancer: A comprehensive review. Cancer Treat Rev. 60:77–89. 2017. View Article : Google Scholar : PubMed/NCBI
7	Keskin O, Tuncbag N and Gursoy A: Predicting protein-protein interactions from the molecular to the proteome level. Chem Rev. 116:4884–4909. 2016. View Article : Google Scholar : PubMed/NCBI
8	Aebersold R and Mann M: Mass-spectrometric exploration of proteome structure and function. Nature. 537:347–355. 2016. View Article : Google Scholar : PubMed/NCBI
9	Riley NM and Coon JJ: Phosphoproteomics in the age of rapid and deep proteome profiling. Anal Chem. 88:74–94. 2016. View Article : Google Scholar : PubMed/NCBI
10	Silva AMN, Vitorino R, Domingues MRM, Spickett CM and Domingues P: Post-translational modifications and mass spectrometry detection. Free Radic Biol Med. 65:925–941. 2013. View Article : Google Scholar : PubMed/NCBI
11	Na S and Paek E: Software eyes for protein post-translational modifications. Mass Spectrom Rev. 34:133–147. 2015. View Article : Google Scholar : PubMed/NCBI
12	Humphrey SJ, James DE and Mann M: Protein phosphorylation: A major switch mechanism for metabolic regulation. Trends Endocrinol Metab. 26:676–687. 2015. View Article : Google Scholar : PubMed/NCBI
13	Butterfield DA, Gu L, Di Domenico F and Robinson RA: Mass spectrometry and redox proteomics: Applications in disease. Mass Spectrom Rev. 33:277–301. 2014. View Article : Google Scholar : PubMed/NCBI
14	Konstantinopoulos PA, Karamouzis MV and Papavassiliou AG: Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat Rev Drug Discov. 6:541–555. 2007. View Article : Google Scholar : PubMed/NCBI
15	Okamura N, Masuda T, Gotoh A, Shirakawa T, Terao S, Kaneko N, Suganuma K, Watanabe M, Matsubara T, Seto R, et al: Quantitative proteomic analysis to discover potential diagnostic markers and therapeutic targets in human renal cell carcinoma. Proteomics. 8:3194–3203. 2008. View Article : Google Scholar : PubMed/NCBI
16	Masui O, White NM, DeSouza LV, Krakovska O, Matta A, Metias S, Khalil B, Romaschin AD, Honey RJ, Stewart R, et al: Quantitative proteomic analysis in metastatic renal cell carcinoma reveals a unique set of proteins with potential prognostic significance. Mol Cell Proteomics. 12:132–144. 2013. View Article : Google Scholar : PubMed/NCBI
17	Atrih A, Mudaliar MA, Zakikhani P, Lamont DJ, Huang JT, Bray SE, Barton G, Fleming S and Nabi G: Quantitative proteomics in resected renal cancer tissue for biomarker discovery and profiling. Br J Cancer. 110:1622–1633. 2014. View Article : Google Scholar : PubMed/NCBI
18	Gottlieb E and Mostoslavsky R: Cancer and metabolism: Why should we care? Semin Cell Dev Biol. 43:1–2. 2015. View Article : Google Scholar : PubMed/NCBI
19	DeBerardinis RJ and Chandel NS: Fundamentals of cancer metabolism. Sci Adv. 2:e16002002016. View Article : Google Scholar : PubMed/NCBI
20	Cantor JR and Sabatini DM: Cancer cell metabolism: One hallmark, many faces. Cancer Discov. 2:881–898. 2012. View Article : Google Scholar : PubMed/NCBI
21	Wallace DC: Mitochondria and cancer. Nat Rev Cancer. 12:685–698. 2012. View Article : Google Scholar : PubMed/NCBI
22	Andrejeva G and Rathmell JC: Similarities and distinctions of cancer and immune metabolism in inflammation and tumors. Cell Metab. 26:49–70. 2017. View Article : Google Scholar : PubMed/NCBI
23	Ganapathy-Kanniappan S and Geschwind JF: Tumor glycolysis as a target for cancer therapy: Progress and prospects. Mol Cancer. 12:1522013. View Article : Google Scholar : PubMed/NCBI
24	Swaney DL, Beltrao P, Starita L, Guo A, Rush J, Fields S, Krogan NJ and Villén J: Global analysis of phosphorylation and ubiquitylation cross-talk in protein degradation. Nat Methods. 10:676–682. 2013. View Article : Google Scholar : PubMed/NCBI
25	Robles MS, Humphrey SJ and Mann M: Phosphorylation is a central mechanism for circadian control of metabolism and physiology. Cell Metab. 25:118–127. 2017. View Article : Google Scholar : PubMed/NCBI